Trial Profile
A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination With Induction Therapy and Consolidation Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia With an IDH1 and/or IDH2 Mutation
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Oct 2023
Price :
$35
*
At a glance
- Drugs Enasidenib (Primary) ; Ivosidenib (Primary) ; Cytarabine; Daunorubicin; Etoposide; Idarubicin; Mitoxantrone
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Agios Pharmaceuticals
- 10 Oct 2023 Planned End Date changed from 1 Jul 2023 to 1 Jul 2024.
- 01 Apr 2022 Results of pk/pd evaluation in patients with newly diagnosed acute myeloid leukemia published in the Clinical Pharmacology in Drug Development
- 14 Dec 2021 Updated Results (As of 16-Jan-2020) of response and survival from Ivosidenib cohort and enasidenib cohort, presented at the 63rd American Society of Hematology Annual Meeting and Exposition